Macular degeneration trials in Germany

In Germany 22 Also abroad 218

22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Where
Bonn, Freiburg im Breisgau, Hanover, Heidelberg, Neubrandenburg, Tübingen, Ulm
Age
55 years to 64 years
People
110 worldwide
Run by
Galimedix Therapeutics Inc
See details and how to joinNCT06659549 · EU 2024-519128-26-00
Phase 2Taking people
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Where
Bonn, Ludwigshafen Am Rhein, Munster, Tuebingen
Age
50 years and over
People
272 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07441642 · EU 2025-523704-77-00
Phase 3Taking people
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Where
Chemnitz, Duesseldorf, Goettingen, Hanover, Rostock, Wuerzburg
Age
50 years and over
People
250 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06847542 · EU 2024-516924-32-00
Phase 3Taking people
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Where
Berlin, Bonn, Duesseldorf, Frankfurt am Main, Goettingen, Hamburg, Heidelberg, Homburg, Ludwigshafen Am Rhein, Mainz, Marburg, Muenster, Munster, Neubrandenburg, Sulzbach, Ulm, Wuerzburg
Age
50 years to 85 years
People
975 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06541704 · EU 2023-509547-27-00
Phase 2/3Taking people
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Where
Bonn, Goettingen, Hanover, Leipzig, Ludwigshafen Am Rhein, Muenster, Munster, Tuebingen
Age
60 years and over
People
274 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06635148 · EU 2022-500747-21-00
No phaseTaking people
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
Where
Bonn
Age
50 years and over
People
1,000 worldwide
Run by
University of Wisconsin, Madison
See details and how to joinNCT06924021
Phase 3Taking people
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Where
Berlin, Bonn, Freiburg im Breisgau, Goettingen, Hamburg, Hanover, Ludwigshafen Am Rhein, Luebeck, Muenster, Munich, Tuebingen, Ulm
Age
50 years and over
People
561 worldwide
Run by
AbbVie
See details and how to joinNCT07007065 · EU 2024-512298-28-00
Phase 3Taking people
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Where
Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen Am Rhein, Muenster, Munich, Munster, Sulzbach, Tuebingen, Ulm
Age
50 years and over
People
1,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03683251 · EU 2023-507131-38-00
Phase 3Taking people
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Where
Düsseldorf, Frankfurt, Neubrandenburg
Age
50 years and over
People
480 worldwide
Run by
4D Molecular Therapeutics
See details and how to joinNCT07064759
Phase 2/3Taking people
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Where
Hamburg, Münster
Age
50 years and over
People
960 worldwide
Run by
EyeBiotech Ltd.
See details and how to joinNCT07440225
Phase 2Enrolling by invitation
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Where
Luebeck, Tuebingen
Age
55 years and over
People
225 worldwide
Run by
Gyroscope Therapeutics Limited
See details and how to joinNCT05481827 · EU 2024-510946-15-00
Phase 3Taking people
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
Where
Berlin, Bonn, Hamburg, Ludwigshafen Am Rhein, Muenster, Munich, Stuttgart, Sulzbach, Ulm, Würzburg
Age
50 years to 120 years
People
210 worldwide
Run by
King's College Hospital NHS Trust
See details and how to joinNCT04663750 · EU 2023-504751-28-00
Phase 2Taking people
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Where
Aachen, Ahaus, Baden-Baden, Bonn, Duesseldorf, Frankfurt am Main, Marburg, Wuerzburg
Age
55 years and over
People
324 worldwide
Run by
ONL Therapeutics
See details and how to joinNCT06659445 · EU 2024-513174-22-00
Phase 2Taking people
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Where
Bonn, Giessen, Köln, Mainz, Muenster, Munich, Sulzbach, Tuebingen
Age
60 years and over
People
240 worldwide
Run by
ADARx Pharmaceuticals, Inc.
See details and how to joinNCT06990269 · EU 2025-521779-30-00
No phaseTaking people
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
Where
Hamburg, München, Stuttgart, Tübingen, Ulm
Age
60 years and over
People
70
Run by
Okuvision GmbH
See details and how to joinNCT07531927
No phaseTaking people
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
Where
Leverkusen
Age
18 years and over
People
50,000
Run by
Bayer
See details and how to joinNCT07308639
Phase 2/3Taking people
A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD)
Where
Bonn, Frankfurt am Main, Hamburg, Hanover, Munich, Munster, Tuebingen
Age
18 years and over
People
130 worldwide
Run by
Eyebiotech Limited
See details and how to join2025-524575-22-00 · EU 2025-524575-22-00
No phaseEnrolling by invitation
Real-time Acoustic Biofeedback for Enhancing Fixation Stability: A Proof-of-concept Study to Improve Ophthalmic Imaging Diagnostic Quality
Where
Göttingen
Age
18 years and over
People
22
Run by
University Medical Center Goettingen
See details and how to joinNCT07529041
No phaseTaking people
Enhanced Vision and Imaging Tests for Enabling Treatment Trials in Early and Intermediate AMD
Where
Bonn
Age
18 years and over
People
150
Run by
Maximilian Pfau
See details and how to joinNCT07515521
No phaseTaking people
International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study
Where
Hamburg, Sulzbach, Trier, Würzburg
Age
55 years and over
People
44 worldwide
Run by
VisionCare, Inc.
See details and how to joinNCT07164378
No phaseNot yet taking people in Germany
This Project At LMU Looks At How Using AI 2nd Opinion Report to Analyze Retinal Eye Scans Impact Doctors' Decisions About Treatment for Patients with a Specific Eye Disease (nAMD)
Where
Munich
Age
18 years and over
People
100
Run by
Johannes Schiefelbein
See details and how to joinNCT06817915
Phase 2Enrolling by invitation
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
Where
Bonn, Freiburg im Breisgau, Hamburg, Ludwigshafen Am Rhein, Muenster, Ulm
Age
50 years and over
People
865 worldwide
Run by
AbbVie
See details and how to joinNCT03999801 · EU 2023-505750-17-00